Biotechnology Switzerland-based Myovant Sciences (NYSE: MYOV) says that its New Drug Application (NDA) for once-daily, oral relugolix combination tablet (relugolix 40mg, estradiol 1.0mg, and norethindrone acetate 0.5mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids has been accepted for review by the US Food and Drug Administration. 19 August 2020